MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

GENOMICS PROTEOMICS & BIOINFORMATICS, published by Elsevier, stands at the forefront of cutting-edge research in the fields of genomics, proteomics, and bioinformatics. This esteemed journal, with an impact factor reflecting its significant influence, has embraced an Open Access model since its inception in 2003, ensuring that knowledge is freely accessible to a global community of researchers, professionals, and students. Based in China, it has been recognized for its exemplary contributions, achieving Q1 quartile rankings in major categories such as Biochemistry, Computational Mathematics, Genetics, and Molecular Biology as of 2023. Moreover, its commendable Scopus rankings position it among the top journals in its fields, with outstanding percentile performances that highlight its scholarly impact. As it continues to converge from 2003 to 2024, the journal aims to foster innovation and collaboration, making it an essential platform for disseminating vital insights and advancements in molecular life sciences.

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

All Life is a distinguished academic journal published by TAYLOR & FRANCIS LTD, based in the United Kingdom, focusing on the interdisciplinary realms of agricultural and biological sciences, biochemistry, genetics, and neuroscience. With the ISSN 2689-5293 and E-ISSN 2689-5307, this open-access journal aims to disseminate high-quality research from 2020 to 2024, facilitating a wider reach and impact across various fields. Notably, it holds a Q3 ranking in both Agricultural and Biological Sciences, as well as Biochemistry, Genetics and Molecular Biology, and a Q4 ranking in Neuroscience, reflecting its growing presence in these disciplines. All Life aims to foster collaboration among researchers, professionals, and students, encouraging innovative approaches in understanding life sciences. By delivering timely insights and thought-provoking discussions, the journal plays a crucial role in advancing knowledge and promoting interdisciplinary dialogue in the evolving landscape of life sciences research.

Current Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.

Protein Journal, published by Springer, stands as a significant academic resource in the fields of Analytical Chemistry, Biochemistry, Bioengineering, and Organic Chemistry. Since its inception in 1996, the journal has dedicated itself to the dissemination of high-quality research focused on protein chemistry and its biomedical applications. With an impressive impact reflected in its classification as a Q2 journal in Analytical Chemistry and Q3 in both Biochemistry and Bioengineering as of 2023, it provides an essential platform for researchers and practitioners to share their findings. The journal embraces the open-access model, enhancing accessibility to cutting-edge research. The Protein Journal is crucial for academicians, industry professionals, and students, catering to their need for rigorous scientific discourse and innovative discoveries in protein studies. With an established track record of converging over two decades of knowledge and research, it continues to influence and shape the advancements in this vital area of science.

AMYLOID - JOURNAL OF PROTEIN FOLDING DISORDERS, published by Taylor & Francis Ltd, is a premier academic journal dedicated to the crucial field of protein folding disorders, offering a vital platform for researchers and healthcare professionals. With an impressive impact factor and classified in the Q1 quartile across both Internal Medicine and Miscellaneous Medicine categories, this journal ranks within the top 15% of its field according to Scopus, with a remarkable rank of #18 out of 167. Covering interdisciplinary approaches that intersect molecular biology, neuroscience, and clinical implications of amyloidosis and related disorders, AMYLOID encourages the dissemination of innovative research findings from 1994 to 2024 and beyond. Despite lacking Open Access options, the journal remains a significant resource for advancing the understanding of protein misfolding diseases, influencing clinical practice and therapeutic developments. With its longstanding commitment to high-quality research, AMYLOID continues to be an essential reading for scholars, practitioners, and students who aim to make significant contributions to this evolving field.

Comparative Biochemistry and Physiology D-Genomics & Proteomics, published by Elsevier Science Inc, is a premier journal in the realm of molecular biology and comparative physiology, with a focus on genomic and proteomic sciences. Recognized for its high-impact contributions, it holds a Q1 ranking in Animal Science and Zoology and was established with the vision of bridging gaps in our understanding of biological systems through experimental and comparative approaches. With an impressive Scopus ranking, this journal not only ranks among the top 12% in Animal Science and Zoology but also demonstrates commendable standings across various categories including Aquatic Science and Molecular Biology. The journal’s commitment to disseminating high-quality research makes it an essential resource for researchers, professionals, and students alike, allowing them to access critical studies that influence advancements in genomics and proteomics. While it operates under a traditional subscription model, its impactful findings are crucial for those aiming to enrich their knowledge and research capabilities in these pivotal scientific fields. Join us in exploring the transformative insights and developments that this esteemed journal has to offer for the study of genomics and proteomics.

Cell Reports Methods is a cutting-edge journal published by CELL PRESS, focusing on innovative methodologies in the vast fields of biochemistry, genetics, biotechnology, and radiological sciences. Launched in 2021, it has rapidly ascended to attain a Q1 ranking across multiple disciplines in the latest 2023 metrics, reflecting its influential contribution to the scientific community. With an emphasis on practical and rigorous experimental approaches, this journal serves as a vital resource for researchers looking to advance their methodologies and collaborate on significant findings in their respective specialties. Despite not being an open-access publication, Cell Reports Methods ensures broad accessibility through institutional subscriptions, allowing researchers from various backgrounds to engage with high-quality scholarly work. The journal presents a unique platform for sharing insights from interdisciplinary methods that foster innovation and discovery, ultimately shaping the future of scientific research.

Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.